A retrospective analysis
of those who participated in
phase III trials in 2011 found that those who had never had a dengue infection at the time
of vaccination were in rare cases at risk
of enhanced
disease, although the Dengvaxia vaccine did reduce infections and cases
of serious illness in those who had previously suffered from dengue.
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Jul. 17, 2017 — Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with
serious, genetically - defined
diseases, today announced the initiation
of the Company's PRECISION - HD program, which includes PRECISION - HD1 and PRECISION - HD2, the Company's two
Phase 1b / 2a clinical trials evaluating WVE - 120101 and WVE - 120102, respectively, for patients with Huntington's
disease (HD).